Testing effectiveness (Phase 2)Not Yet RecruitingNCT07685704
What this trial is testing
Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study
Who this might be right for
Gastric CancerGastroesophageal Junction AdenocarcinomaHER2-positive Gastric Cancer
Zhifeng Zhao, PhD 46